Abstract
Gallium nitrate, a drug with antitumor activity, is presently undergoing clinical trials as a chemotherapeutic agent for the treatment of certain malignancies. Since there are very limited published animal toxicity data available, this study was conducted to investigate the potential adverse developmental effects of this drug. Pregnant Swiss mice were administered intraperitoneally gallium nitrate at 12.5, 25, 50, and 100 mg/kg/day on days 6, 8, 10, 12, and 14 of gestation. Monitors for maternal toxicity were body weight, food consumption and clinical signs. At sacrifice (day 18) maternal weight, liver and kidney weights, and gravid uterine weights were measured. Gestational parameters monitored were numbers of total implants, resorptions, postimplantation losses, and dead fetuses. Live fetuses were sexed, weighed, and examined for external, internal and skeletal malformations and variations. Maternal toxicity was noted in all the gallium nitrate-treated groups. Embryo/fetal toxicity was evidenced by a decrease in the number of viable implants, a reduction in fetal weight, and an increase in the number of skeletal variations (12.5, 25, 50 and 100 mg/kg). No significant increase in the incidence of malformations was observed at 12.5, 25, or 50 mg/kg. The no-observable-adverse-effect level (NOAEL) for both maternal and developmental toxicity of gallium nitrate was <12.5 mg/kg.
Similar content being viewed by others
References
Adamson RH, Canellos GP, Sieber SM (1975) Studies on the antitumor activity of gallium nitrate (NSC-15 200) and other group IIIa metal salts. Cancer Chemother Rep 59: 599–610
Ando A, Nitta K, Ando I, Sanada S, Katsuda S, Tonami N, Hiraki T, Hisada K, Ogawa H (1990) Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med 17: 21–27
Bockman RS (1980) Hypercalcemia in malignancy. Clin Endocrinol Metab 9: 317–333
Bockman RS, Repo MA, Warrell RP Jr, Pounds JG, Schidlovsky G, Gordon BM, Jones KW (1990) Distribution of trace levels of therapeutic gallium in bone as mapped by synchroton X-ray microscopy. Proc Natl Acad Sci USA 87: 4149–4153
Crary DD (1962) Modified benzyl alcohol clearing of alizarin-stained specimens without loss of flexibility. Stain Technol 37: 124–125
Chitambar CR, Matthaeus WG, Antholine WE, Graff K, O'Brien WJ (1988) Inhibition of leukemic HL60 cell growth by transferrin-gallium: effects on ribonucleotide reductase and demonstration of drug synergy with hydroxyurea. Blood 72: 1930–1936
Domingo JL, Corbella J (1991) A review of the health hazards from gallium exposure. Trace Elem Med 8: 56–64
Domingo JL, Llobet JM, Corbella J (1987) Acute toxicity of gallium in rats and mice. J Toxicol Clin Exp 7: 411–418
Edwards CL, Hayes RL (1969) Tumor scanning with67Ga citrate. J Nucl Med 10: 103–105
Ferm VH, Carpenter SJ (1970) Teratogenic and embryopathic effects of indium, gallium and germanium. Toxicol Appl Pharmacol 16: 166–170
Foster BJ, Clagett-Carr K, Hoth D, Leyland-Jones B (1986) Gallium nitrate: the second metal with clinical activity. Cancer Treat Rep 70: 1311–1319
Hart MM, Smith CF, Yancey ST, Adamson RH (1971) Toxicity and antitumor activity of gallium nitrate and periodically related metal salts. J Natl Cancer Inst 47: 1121–1127
Khera KS (1981) Common fetal aberrations and their teratological significance: a review. Fundam Appl Toxicol 1: 13–18
Khera KS (1984) Maternal toxicity — A possible factor in fetal malformations in mice. Teratology 29: 411–416
Krakoff IH, Newman RA, Goldberg RS (1979) Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer 44: 1722–1727
Lavender JP, Lowe J, Barker JR (1971) Gallium-67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol 44: 361–366
Lundberg JH, Chitambar CR (1990) Interaction of gallium nitrate with fludarabine and iron chelators: effects on the proliferation of human leukemic HL60 cells. Cancer Res 50: 6466–6470
Mahon DF, Subramanian G, McAfee JG (1973) Experimental comparisons of radioactive agents for studies of the placenta. J Nucl Med 14: 651–659
Newman RA, Brody AR, Krakoff IH (1979) Gallium nitrate (NSC-15200) induced toxicity in the rat. A pharmacologic, histopathologic and microanalytical investigation. Cancer 44: 1728–1740
Otten JA, Tyndall RL, Estes PE, Swartzendruber DC (1973) Localization of gallium-67 during embryogenesis. Proc Soc Exp Biol Med 142: 92–95
Tyl RW, Price CJ, Marr MC, Kimmel CA (1988) Developmental toxicity evaluation of dietary di(2-ethylhexyl)phtalate in Fischer 344 rats and CD-1 mice. Fundam Appl Toxicol 10: 395–412
Tyndall RL, Chaskes SJ, Carlton JF, Nelson P, Daniel JC (1976) Gallium-67 distribution in pregnant mammals. J Exp Zool 195: 417–424
Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M, Staszewski H (1984) Gallium nitrate inhibits calcium resorptions from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 73: 1487–1490
Warrell RP Jr, Isaacs M, Coonley CJ, Alcock NW, Bockman RS (1985) Metabolic effects of gallium nitrate administered by prolonged infusion. Cancer Treat Rep 69: 653–655
Warrell RP Jr, Skelos A, Alcock NW, Bockman RS (1986) Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res 46: 4208–4212
Wilson JG (1965) Embryological considerations in teratology. In: Wilson JG, Warkany J (eds) Teratology: principles and techniques. Univ. of Chicago Press, Chicago, pp 251–277
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gómez, M., Sánchez, D.J., Domingo, J.L. et al. Developmental toxicity evaluation of gallium nitrate in mice. Arch Toxicol 66, 188–192 (1992). https://doi.org/10.1007/BF01974013
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01974013